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Innovations
Prana Biotechnology, Limited:
Metal Attenuation in the Treatment
of Neurodegenerative Disease
damage and are the primary drivers called reactive metals that can lead
to free-radical production, [which is]of toxicity in these neurodegenera-
very dangerous for cells and nervetive diseases,” explains Dr. Alsenas.
cells,” says Dr. Tanzi. “They includeImbalances in prooxidant/antioxi-
iron and copper. Of those two, cop-dant homeostatis cause oxidative
In recent months, new energy has
centered on the treatment of Alzhei-
mer’s disease (AD) and other neuro-
degenerative diseases; in part, this
new interest is sparked by political
debates and celebrity appeals for per has a greater attraction to A,stress, leading to toxic, reactive
new research measures. “But our so in my opinion, copper is probablyoxygen species, including hydrogen
work began about 10 years ago the main target.”peroxide, nitric oxide, superoxide,
when Ashley Bush and I first began Though other research groupsand hydroxyl radical. “That science
studying the interaction of metals confirm the detrimental interactionunderpins all of the drug develop-
with the amyloid- (A) peptide that of metals with A, the metal/A hy-ment we have done, starting from
makes up the amyloid of the senile pothesis is far from mainstream. But,the work in Drs. Tanzi’s and Bush’s
plaques seen in Alzheimer’s dis- recently, scientists seem to agree onlabs, and also Dr. Masters’, and now
ease,” explains Rudolph Tanzi, PhD, two key interactions. First, zinc isinternally at Prana,” says Dr. Alsenas.
professor of neurology at Harvard required to initiate the aggregationHe believes MPACs are likely to
Medical School and Director of the and precipitation of the A into amy-have a role in treating several disor-
Genetics and Aging Research Unit loid. And, second, copper acts asders, neurodegenerative and degen-
at Massachusetts General Hospital a catalyst producing peroxide. “Buterative alike. “Many of the diseases
(MGH), Boston. Along with Dr. Bush, what these findings imply for thera-we are focused on are associated
Dr. Tanzi is also one of two co- peutic discovery is where people be-
founders of Melbourne, Australia- gin to debate,” says Dr. Alsenas.
based Prana Biotechnology, Ltd., a Attenuators, Not Chelators
“Overall, our primary pur-company focused on developing new “Up until 2000 or 2001, support was
lacking for this approach,” explainstherapies for AD in particular and neu- pose at Prana is the
rodegenerative diseases in general. Dr. Ross Murdoch, COO at Pranadevelopment of metal
“The idea behind our work was who oversees drug development
protein-attenuating com-that metals bind the A protein and and research, including the com-
pany’s lead MPAC, PBT-1 (clioqui-drive some of the plaque pathology pounds, or MPACs, for
seen in Alzheimer’s disease,” says nol). But in a 2001 study published inAlzheimer’s.”— Jonas V.
Dr. Tanzi. After successful in vitro Neuron, Bush and colleagues found
Alsenas, CEO, Pranaand animal experiments in the Tanzi that clioquinol decreased A pep-
and Bush laboratories at MGH, the tide sediment by 65% when plaques
pair decided to pursue this research start to form in 12-month-old mice
with aging, but as we become morein hopes of finding a potential cause and by 41% in 21-month-old mice.
aware of the usefulness of thesefor AD. From that effort, Prana was The authors then concluded that cli-
compounds and the breadth of tox-founded. Prana, which has about 15 oquinol inhibits and possibly re-
icity caused by inappropriate metal-full-time staff, officially incorporated verses accumulation of A deposits
protein interactions, it is now be-in Australia in 1997. The seminal sci- in the brains of these mice.
coming evident to us that we are inence was licensed from MGH and The evidence is beginning to
a position in which we may havealso from the laboratory of Professor suggest that intracellular levels of
assets that may allow us to moveColin Masters at the University of copper and zinc are depleted in
past simply age-related diseases toMelbourne, chairman of Prana’s Sci- transgenic mice with AD or Alzhei-
those that are associated muchentific Advisory Board. mer’s-similar pathology. After PBT-1
more with oxidative stress,” he says.MPACs against treatment, the plaques begin to dis-
He adds that many age-related dis-Neurodegenerative Disease aggregate and are cleared. “But the
orders, such as AD, Parkinson’s dis-According to Jonas V. Alsenas, metals are not necessarily just
ease, and amyotrophic lateral scle-DVM, Prana’s CEO, “Overall, our pri- cleared out of the body,” says Dr.
rosis (ALS), may develop at leastmary purpose at Prana is the devel- Murdoch. “There has been a misper-
partially from the cumulative effectsopment of metal protein-attenuating ception that clioquinol and drugs of
of oxidative stress.compounds, or MPACs, for Alzhei- this class would work as chelators
Dr. Tanzi explains that a numbermer’s.” Prana’s founding science is and essentially mop up and clear
of metals—notably zinc, copper,based on the inappropriate interac- metals out of the brain. But, instead,
and iron—cause the aggregation oftions of metals and proteins in the we see intracellular levels of the met-
this small A protein into amyloid tobrain. “We believe these interactions als rise in the neurons, so that is
why we call them attenuating com-cause oxidative stress and oxidative different degrees. “But it is the so-
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pounds.” Clioquinol appears to dis- in the mild-to-moderately affected brain back,” he says. He believes
that given the ability of a neighboringassociate copper and zinc from the patients compared with those re-
ceiving placebo. “This was not unex-amyloid to help normalize metal ac- nerve cell to compensate for a lost
synaptic connection, as long as thetivity and levels in the brain. pected since patients early in the
course of disease are not declining“The compounds we are using are surviving nerve cells are no longer
under attack by toxic amyloid fibrilsnot even close; they aren’t in the very rapidly,” theorizes Dr. Alsenas.
Clioquinol is by no means new, assame universe with chelators, which combining with copper and other re-
active metals, “you will be on themop up all the metals with an incred- it was originally marketed globally
by Ciba-Geigy from the 1930s–ible amount of affinity,” says Dr. road to recovery,” he says. “But the
extent of that recovery and how opti-Tanzi enthusiastically. “The advan- 1970s as an antibiotic to treat diar-
rhea. Clioquinol was removed fromtage of having just enough attraction mistic to be is really contentious.”
Next up: PBT-2for copper, zinc, and the A peptide the U.S. market in 1971 because of
a link with subacute myelo-opticis that PBT-1 and the other MPACs Although Prana settled a patent dis-
pute over PBT-1 in August 2004 withwe are developing can get to the neuropathy seen primarily in Ja-
panese patients. Prana has beenright place in the brain and basically a Greek company called P.N. Gero-
lymatos S.A., the company is pursu-pull away the zinc and copper to dis- pleased with the PBT-1 side effect
profile in its trial. “It is all a mattersolve it or to prevent it from further ing next-generation MPACs, includ-
ing its PBT-2. “Understanding thataggregating.” Chelators have affin- of dose, and though clioquinol was
taken off the market decades ago,ity constants in the range of 1020– clioquinol has been used in millions
of patients, it still may not be the1030. In contrast, PBT-1’s affinity it was originally used at very high
doses,” explains Dr. Murdoch. “Forconstant is about 1011 or 1012, ideal, so we are developing new
compounds that have the samemany dozens of orders of magnitude Alzheimer’s disease, we have re-
duced that dose.”lower in terms of its attraction than mechanism of action but are struc-
turally different,” explains Dr. Mur-a chelator. In October 2004, Prana released
results of its CQADEX trial, a 48-First PBT-1 Human doch. “PBT-1 is an 8-hydroxyquino-
line, and we developed and studiedStudies Encouraging week extension study of its CQAD
trial. Though only 9 patients com-Results from a 36-patient Phase II over 300 novel 8-hydroxyquinolone
structures before we found PBT-2,trial, published in December 2003 in pleted the full 84-week study begin-
ning with CQAD, it showed thatthe Archives of Neurology, showed which, in our minds, is the optimal
candidate.” PBT-2 was brought intothat PBT-1 might at least delay AD PBT-1 slowed the expected disease
progression by about half. In the firstprogression in more severely af- development just over a year ago,
has gone through preclinical toxicityfected patients. The placebo-con- half of 2005, Prana plans on initiating
a Phase II/III, 435-patient study—trolled, dose-escalation study known testing, and is expected to be in a
Phase I safety trial with healthy vol-as CQAD grouped subjects into two PLACQUE (Progression Limiting in
Alzheimer’s: ClioQUinol’s Efficacy)—clusters: those with mild-to-moder- unteers in early 2005. Prana is also
developing new compounds asideate disease (less than 25 on the to examine the effect of PBT-1 in mod-
erate-to-severe Alzheimer’s diseaseADAS-cog scale), and those with from 8-hydroxyquiniolone drugs.
“Our intention is that those com-moderate-to-severe disease (greater patients. Patients will be random-
ized into placebo and two treatmentthan 25 on the ADAS-cog scale). All pounds will not only be tested for
their efficacy in AD, but they will alsostudy participants received baseline arms (125 mg and 250 mg BID) and
will be treated for 52 weeks.Aricept therapy, a commonly used be optimized for other diseases,
such as Parkinson’s,” says Dr.AD drug. Dr. Murdoch cautions that it is im-
portant to remember that the toxicity“The analysis showed that in sev- Murdoch.
eral of the time points assessed associated with AD is in effect the
destruction of brain neurons. “So,in the moderate-to-severe patients, Chemistry & Biology invites your
comments on this topic. Pleasethere was a statistically significant the concept that a drug can turn tox-
icity around and assist in the devel-7-point difference compared with write to the editors at chembiol@
cell.com.the placebo group,” says Dr. Alsenas. opment of new neurons is certainly
not what we believe is happening,”Looking at biochemical secondary
Alice A. McCarthy is a freelance scienceendpoints, PBT-1 appeared to in- he cautions. “Instead, we believe
writer based in Gloucester, MA (alice@duce statistically significant differ- these therapies are designed hope-
alicemccarthy.com).
ences in soluble A plasma levels in fully to stop the disease in its tracks
and to break up any amyloid aggre-the two groups. “This suggested a
biochemical basis for what we were gation that has already occurred.”
But Dr. Tanzi optimistically supportsseeing cognitively—that PBT-1 was
and is disease modifying,” ac- the idea that stopping the disease
process puts the brain back on thecording to Dr. Alsenas. “I think we
saw a clear signal that in patients road to recovery. “If you stop the
acute attack on nerve cells— whichwho are beginning to decline rapidly,
we could show an extremely mean- have an incredible amount of plas-
ticity and compensatory proper-ingful difference between them and
the placebo group.” However, no ties—it remains debatable, and con-
troversial, how far you can bring thedifferences in endpoints were found
